Brief: Beam Therapeutics To Encore Data From Beacon Phase 1/2 Clinical Trial Of Beam-101
23/01/2025 12:01
Jan 23 (Reuters) - Beam Therapeutics Inc BEAM.O :
* BEAM THERAPEUTICS TO ENCORE DATA FROM BEACON PHASE 1/2
CLINICAL
TRIAL OF BEAM-101 IN SICKLE CELL DISEASE AT 2025 TANDEM MEETINGS
OF ASTCT AND CIBMTR
Source text: ID:nGNX1B78fH
Further company coverage: BEAM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Beam Therapeutics
See all newsBeam Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Beam Therapeutics Q1 net loss narrows beating analyst estimates
U.S. STOCKS ON THE MOVE-ADMA Biologics, Nanobiotix, DraftKings
U.S. STOCKS ON THE MOVE-BWX, Generac, Cintas
U.S. STOCKS ON THE MOVE-Arm, On Holding, Sarepta